| Date | Time | Source | Headline | Symbol | Company |
| 12/16/2004 | 4:03PM | PR Newswire (US) | CV Therapeutics Appoints Thomas E. Shenk, Ph.D. to Board of Directors | NASDAQ:CVTX | CV Therapeutics (MM) |
| 12/15/2004 | 4:02PM | PR Newswire (US) | ASCOT Study Which Included Perindopril Stopped Early Due to Significant Benefit in Treatment Arm of Study | NASDAQ:CVTX | CV Therapeutics (MM) |
| 12/13/2004 | 5:55PM | PR Newswire (US) | Supplemental New Drug Application for ACEON(R) Label Expansion Based on EUROPA Outcomes Data Submitted to U.S. FDA | NASDAQ:CVTX | CV Therapeutics (MM) |
| 12/06/2004 | 4:04PM | PR Newswire (US) | CV Therapeutics to Host Conference Call on Monday, December 6, 2004 to Discuss ACEON(R) Co-Promotion Agreement | NASDAQ:CVTX | CV Therapeutics (MM) |
| 12/06/2004 | 4:02PM | PR Newswire (US) | CV Therapeutics and Solvay Pharmaceuticals Enter Into Co-Promotion Agreement for ACEON(R) (perindopril erbumine) Tablets | NASDAQ:CVTX | CV Therapeutics (MM) |
| 11/16/2004 | 11:30PM | PR Newswire (US) | CV Therapeutics Completes Enrollment of ERICA, an Approval-Enabling Study of Ranexa(TM) (ranolazine) | NASDAQ:CVTX | CV Therapeutics (MM) |
| 10/26/2004 | 5:04PM | PR Newswire (US) | CV Therapeutics Reports 2004 Third Quarter Financial Results | NASDAQ:CVTX | CV Therapeutics (MM) |
| 10/26/2004 | 5:02PM | PR Newswire (US) | Approval-Enabling Study of Ranexa(TM) Enrolling Ahead of Schedule | NASDAQ:CVTX | CV Therapeutics (MM) |
| 10/18/2004 | 8:00AM | PR Newswire (US) | CV Therapeutics to Announce 2004 Third Quarter Financial Results on Tuesday, October 26, 2004 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 10/11/2004 | 8:00AM | PR Newswire (US) | CV Therapeutics Initiates MERLIN TIMI-36 Study of Ranexa(TM) | NASDAQ:CVTX | CV Therapeutics (MM) |
| 08/24/2004 | 8:00AM | PR Newswire (US) | Circulation Publishes Study of Ranolazine Demonstrating Important Cardiac Ion Channel Effects | NASDAQ:CVTX | CV Therapeutics (MM) |
| 08/02/2004 | 5:02PM | PR Newswire (US) | CV Therapeutics Initiates Approval-Enabling Trial of Ranexa(TM) | NASDAQ:CVTX | CV Therapeutics (MM) |
| 07/29/2004 | 5:04PM | PR Newswire (US) | CV Therapeutics and FDA Agree to Special Protocol Assessment for Outcomes Study to Support Potential Use of Ranexa(TM) as First- | NASDAQ:CVTX | CV Therapeutics (MM) |
| 07/29/2004 | 5:03PM | PR Newswire (US) | CV Therapeutics Reports 2004 Second Quarter Financial Results | NASDAQ:CVTX | CV Therapeutics (MM) |
| 07/22/2004 | 8:00AM | PR Newswire (US) | CV Therapeutics to Announce 2004 Second Quarter Financial Results on Thursday, July 29, 2004 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 06/08/2004 | 8:30AM | PR Newswire (US) | CV Therapeutics Announces Sale of $25 Million in Convertible Notes From Additional Purchase Option | NASDAQ:CVTX | CV Therapeutics (MM) |
| 06/04/2004 | 10:15AM | PR Newswire (US) | MORNING UPDATE: Man Securities Issues Alerts for TLAB, CVTX, BMRN, TER, and HLTH | NASDAQ:CVTX | CV Therapeutics (MM) |
| 06/02/2004 | 5:05PM | PR Newswire (US) | CV Therapeutics and FDA Agree to Special Protocol Assessment for Approval-Enabling Study of Ranexa(TM) | NASDAQ:CVTX | CV Therapeutics (MM) |
| 05/13/2004 | 8:00AM | PR Newswire (US) | CV Therapeutics Announces Private Offering of Senior Subordinated Convertible Notes | NASDAQ:CVTX | CV Therapeutics (MM) |
| 05/11/2004 | 5:04PM | PR Newswire (US) | CV Therapeutics Announces Proposed Private Offering of Senior Subordinated Convertible Notes | NASDAQ:CVTX | CV Therapeutics (MM) |
| 04/30/2004 | 6:30AM | PR Newswire (US) | CV Therapeutics Reports 2004 First Quarter Financial Results | NASDAQ:CVTX | CV Therapeutics (MM) |
| 04/26/2004 | 8:00AM | PR Newswire (US) | CV Therapeutics Initiates Second Phase III Trial of Regadenoson | NASDAQ:CVTX | CV Therapeutics (MM) |
| 04/22/2004 | 6:00PM | PR Newswire (US) | CV Therapeutics to Announce 2004 First Quarter Financial Results on Friday, April 30, 2004 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 04/20/2004 | 6:00PM | PR Newswire (US) | JACC Publishes MARISA Trial Results, Including Anti-Ischemic and Long-Term Survival Data | NASDAQ:CVTX | CV Therapeutics (MM) |
| 03/30/2004 | 7:00AM | PR Newswire (US) | CV Therapeutics Files Application for European Marketing Approval of Ranolazine for Treatment of Chronic Angina | NASDAQ:CVTX | CV Therapeutics (MM) |
| 03/30/2004 | 7:00AM | PR Newswire (US) | CV Therapeutics Files Application for European Marketing Approval of Ranolazine for Treatment of Chronic Angina | NASDAQ:CVTX | CV Therapeutics (MM) |
| 02/24/2004 | 7:00AM | PR Newswire (US) | CV Therapeutics Announces Five Abstracts Accepted for Presentation at American College of Cardiology Scientific Sessions 2004 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 02/10/2004 | 3:59PM | PR Newswire (US) | CV Therapeutics Reports Fourth Quarter and Year End Financial Results for 2003 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 12/12/2003 | 8:45AM | PR Newswire (US) | CV Therapeutics (Nasdaq: CVTX) Upgraded to BUY by Independent Researcher White Mountain Capital | NASDAQ:CVTX | |
| 12/09/2003 | 6:09PM | PR Newswire (US) | FDA Advisory Committee Evaluates Ranexa(TM) | NASDAQ:CVTX | CV Therapeutics (MM) |